
|Articles|September 25, 2014
- Gynecologic Cancers (Issue 1)
- Volume 1
- Issue 1
The Role of Molecular Testing in Gynecologic Cancers
Author(s)Maurie Markman, MD
Maurie Markman, MD, discusses the role of molecular testing in gynecologic cancers.
Advertisement
Maurie Markman, MD, senior vice president for Clinical Affairs and National Director for Medical Oncology, Cancer Treatment Centers of America, Eastern Regional Medical Center, discusses the role of molecular testing in gynecologic cancers.
View more about screening for ovarian cancer > >
Articles in this issue
about 11 years ago
Trabectedin as a Treatment Option for Patients with Ovarian Cancerabout 11 years ago
Dream Team Aims To Change the Face of Ovarian Cancer Researchabout 11 years ago
On The Horizon for Ovarian Cancer: Potentially Promising Treatmentsabout 11 years ago
Cediranib Versus Olaparib in Recurrent Platinum-Sensitive Ovarian CancerAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5








































